Table 4.

Proportion of Patients With Abnormal^* Lipid Profiles at Baseline and 12 and 24 Weeks by Treatment Arm

Assay	Baseline			Week 12			Week 24
	No.	%	P	No.	%	P	No.	%	P
Cholesterol ≥ 200 mg/dL			.72			.74			.41
O3-FAs	43	50.6		42	52.5		41	55.4
Placebo	48	53.3		46	50.0		35	48.6
CRP ≥ 5 mg/L			.46			.35			.37
O3-FAs	24	28.2		27	33.8		14	18.9
Placebo	21	23.3		25	27.2		18	25.0
HDL ≤ 40 mg/dL			.33			.48			.32
O3-FAs	9	10.6		10	12.5		9	12.2
Placebo	14	15.6		15	16.3		13	18.1
LDL ≥ 100 mg/dL			.92			.49			.86
O3-FAs	61	71.8		54	68.4		49	67.1
Placebo	63	72.4		57	63.3		46	65.7
Triglycerides ≥ 150 mg/dL			.66			.11			.31
O3-FAs	32	37.6		19	23.8		20	27.0
Placebo	31	34.4		32	34.8		25	34.7

Abbreviations: CRP, C-reactive protein; O3-FA, omega-3 fatty acid.

^*As defined by National Institute of Health, National Heart Lung and Blood, guidelines.